Pratima Chowdary, M.D., presented Phase I/II safety and efficacy results on FLT180a in hemophilia B (HB) patients. FLT180a is an investigational gene therapy medicinal product candidate that includes AAVS3, a rationally designed capsid designed to deliver higher levels of liver transduction than wild-type adeno-associated virus (AAV), and a codon optimized F9 gene with a gain-of-function mutation.
Studies reported findings of coagulopathy and high incidences of thrombotic complications in hospitalized patients with COVID-19 pneumonia in patients admitted to the intensive care unit (ICU) but, to a lesser extent, also in ward-admitted patients. What is unknown is how the incidence of thrombotic complications in COVID-19 patients compares with that observed in hospitalized patients with other virus infections, including influenza, as some studies suggest that SARS-CoV-2 itself induces a specific procoagulant effect.
Matthias M. Engelen of University Hospitals Leuven in Leuven, Belgium, presented late-breaking results evaluating the residual thrombotic risk and incidence of venous thromboembolism (VTE) in patients following hospitalization for COVID-19.
Hanny Al-Samkari, M.D., of Massachusetts General Hospital in Boston, MA, sought through his Late-Breaking Abstract to examine incidence of radiographically confirmed venous thromboembolism (VTE) and major bleeding in a large nationally representative U.S. cohort, evaluate predictors of VTE in critically ill patients with COVID-19, and assess whether therapeutic anticoagulation affects survival.
Chronic thromboembolic pulmonary hypertension (CTEPH) is considered a potentially curable long-term complication of acute pulmonary embolism (PE), comprising chronic thrombotic obstruction of pulmonary arteries, which triggers small-vessel arteriopathy.